162 related articles for article (PubMed ID: 34329704)
1. Urinary metabolite prognostic biomarker panel for pancreatic ductal adenocarcinomas.
Hipperson L; Hadden WJ; Nahm CB; Gill AJ; Samra JS; Dona A; Mittal A; Sahni S
Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129966. PubMed ID: 34329704
[TBL] [Abstract][Full Text] [Related]
2. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
3. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study.
Guo JC; Zhang P; Zhou L; You L; Liu QF; Zhang ZG; Sun B; Liang ZY; Lu J; Yuan D; Tan AD; Sun J; Liao Q; Dai MH; Xiao GG; Li S; Zhang TP
EBioMedicine; 2020 May; 55():102767. PubMed ID: 32361251
[TBL] [Abstract][Full Text] [Related]
5. Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas.
Mehta S; Bhimani N; Gill AJ; Samra JS; Sahni S; Mittal A
Front Oncol; 2021; 11():708963. PubMed ID: 34290990
[TBL] [Abstract][Full Text] [Related]
6. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
7. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
8. Urine metallomics signature as an indicator of pancreatic cancer.
Schilling K; Larner F; Saad A; Roberts R; Kocher HM; Blyuss O; Halliday AN; Crnogorac-Jurcevic T
Metallomics; 2020 May; 12(5):752-757. PubMed ID: 32211672
[TBL] [Abstract][Full Text] [Related]
9. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.
Roy R; Zurakowski D; Wischhusen J; Frauenhoffer C; Hooshmand S; Kulke M; Moses MA
Br J Cancer; 2014 Oct; 111(9):1772-9. PubMed ID: 25137018
[TBL] [Abstract][Full Text] [Related]
10. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution.
Napoli C; Sperandio N; Lawlor RT; Scarpa A; Molinari H; Assfalg M
J Proteome Res; 2012 Feb; 11(2):1274-83. PubMed ID: 22066465
[TBL] [Abstract][Full Text] [Related]
11. CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma.
Yang G; Wang Y; Xiao J; Zhao F; Qiu J; Liu Y; Chen G; Cao Z; You L; Zheng L; Zhang T; Zhao Y
Cell Oncol (Dordr); 2021 Apr; 44(2):345-355. PubMed ID: 33125631
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
13. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer.
Byeon S; McKay MJ; Molloy MP; Gill AJ; Samra JS; Mittal A; Sahni S
Int J Cancer; 2024 Jul; 155(2):365-371. PubMed ID: 38519999
[TBL] [Abstract][Full Text] [Related]
14. Metabonomic changes from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma in tissues from rats.
Wen S; Li Z; Feng J; Bai J; Lin X; Huang H
Cancer Sci; 2016 Jun; 107(6):836-45. PubMed ID: 27019331
[TBL] [Abstract][Full Text] [Related]
15. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the diagnostic ability of laminin gene family for pancreatic ductal adenocarcinoma.
Yang C; Liu Z; Zeng X; Wu Q; Liao X; Wang X; Han C; Yu T; Zhu G; Qin W; Peng T
Aging (Albany NY); 2019 Jun; 11(11):3679-3703. PubMed ID: 31182680
[TBL] [Abstract][Full Text] [Related]
17. Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
Zhu Y; Wang J; Wang F; Yan Z; Liu G; Ma Y; Zhu W; Li Y; Xie L; Bazhin AV; Guo X
Biochemistry (Mosc); 2019 May; 84(5):575-582. PubMed ID: 31234772
[TBL] [Abstract][Full Text] [Related]
18. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.
Wang L; Wu H; Wang L; Lu J; Duan H; Liu X; Liang Z
Diagn Pathol; 2016 Jul; 11(1):60. PubMed ID: 27391842
[TBL] [Abstract][Full Text] [Related]
19. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression.
Sahni S; Krisp C; Molloy MP; Nahm C; Maloney S; Gillson J; Gill AJ; Samra J; Mittal A
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129682. PubMed ID: 32663515
[TBL] [Abstract][Full Text] [Related]
20. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer.
Sahni S; Moon EA; Howell VM; Mehta S; Pavlakis N; Chan D; Ahadi MS; Gill AJ; Samra J; Mittal A
Eur J Surg Oncol; 2020 Aug; 46(8):1539-1542. PubMed ID: 32061458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]